Thumbnail
Access Restriction
Open

Author Xi, Wei-Hong ♦ Yang, Li-Yun ♦ Cao, Zhong-Yi ♦ Qian, Yong
Source United States Department of Energy Office of Scientific and Technical Information
Content type Text
Language English
Subject Keyword APPLIED LIFE SCIENCES ♦ APOPTOSIS ♦ CARCINOMAS ♦ CELL CYCLE ♦ CELL PROLIFERATION ♦ COLONY FORMATION ♦ DOSES ♦ INHIBITION ♦ METASTASES ♦ PATIENTS ♦ PLANT GROWTH ♦ SIGNALS
Abstract Oral squamous cell carcinoma (OSCC) is one of the most common cancers worldwide and the 5 years survival rate of the patients is about 60% in the USA, due to acquired chemotherapeutic resistance and metastasis of the disease. In this study, we found that tivantinib, a selective MET inhibitor, suppresses OCSS cell proliferation and colony formation, however, anti-tumor activities induced by tivantinib are independent of the inhibition of MET signaling pathway. In addition, tivantinib cause G2/M cell cycle arrest and caspases-dependent apoptosis in OSCC cell lines. We also found that tivantinib dose-dependently suppressed the activation and expression of FAK. In all, these data suggested that tivantinib may be developed as a chemotherapeutic agent to effectively treat certain cancers including OSCC. - Highlights: • Tivantinib suppresses OSCC cell growth independent of the inhibition of HGF/MET signaling pathway. • Tivantinib blocks cell cycle and induces caspases-mediated apoptosis. • Tivantinib elicits its anti-tumor activity with the inhibition of FAK signaling pathway.
ISSN 0006291X
Educational Use Research
Learning Resource Type Article
Publisher Date 2015-02-20
Publisher Place United States
Journal Biochemical and Biophysical Research Communications
Volume Number 457
Issue Number 4


Open content in new tab

   Open content in new tab